Jiangsu hengrui Pharmaceutical Co., Ltd. is an enterprise engaged in pharmaceutical innovation, high-quality drug research and development and other industries. Founded in 1970, it was listed on the Shanghai Stock Exchange in 2000. It is the largest research, development and production base of anti-tumor drugs in China.
Its main business scope includes anti-tumor drugs, cardiovascular drugs and endocrine drugs. Selected as "Top 500 Private Enterprises in China in 2020", ranking 424th.
202 110/9 and Hengrui Pharma Announcement 2021The revenue in the third quarter was 690 1 100 million yuan, down14.84% year-on-year; The net profit returned to the mother was 65.438+0.54 billion yuan, down 3.57% year-on-year. [1] On June 9, 2022,1,202 1 Hurun China Top 500 was released, and jiangsu hengrui Pharmaceutical Co., Ltd. ranked 28th.
Jiangsu hengrui Pharmaceutical Co., Ltd. is a medical and health enterprise engaged in medical innovation and research and development, production and promotion of high-quality drugs. Founded in 1970, it was listed on Shanghai Stock Exchange in 2000. By the end of 20 19, * * had more than 24,000 employees worldwide. It is a well-known supplier of anti-tumor drugs, surgical drugs and contrast agents in China, and also the leading unit of the Industry-University-Research Alliance of National Anti-tumor Drug Technology Innovation. In 20 19, the company achieved operating income of 23.29 billion yuan and tax revenue of 2.43 billion yuan, and was selected as the top 50 pharmaceutical companies in the world, ranking 47th. In the practice of market competition, Hengrui Pharma insists on innovation as the driving force to build its core competitiveness.
In recent years, the company's annual investment in R&D accounts for about 65,438+05% of its sales. In 2065,438+09, it invested 3.9 billion yuan in R&D, accounting for 65,438+06.7% of its sales revenue. The company has established R&D centers or branches in the United States, Europe, Japan and China, and built an R&D team of more than 3,400 people, including more than 2,000 doctors and masters, and more than 200 returnees. In recent years, the company has undertaken 44 major national projects, and six innovative drugs, such as aricoxib, apatinib, tiofegelastine, Pyrrolidine, carrelizumab, and Rimazzolam Toluene Sulfonate, have been approved for marketing. Many innovative drugs are under clinical development, and many innovative drugs are under clinical development in the United States. The company has applied for 894 domestic invention patents, including 20 domestic effective invention patents 1, 286 foreign patents authorized by Europe, America, Japan, 2 second-class national scientific and technological progress awards for proprietary core technologies, and China patent gold award1.
Based on the management principle of "honesty and trustworthiness, quality first", Hengrui Pharma ranks among the best in the domestic market share in the fields of anti-tumor drugs, surgical anesthesia drugs, special infusion and contrast media. At present, the company has 19 preparation products such as injections, oral preparations and inhalation anesthetics listed in Europe, America and Japan, realizing the large-scale sales of domestic injections in Europe, America and Japan. Perseverance and far-reaching, Yi Rui's life. Hengrui Pharma has been adhering to the concept of "scientific research-based, creating a healthy life", with the overall goal of building a multinational pharmaceutical group of China people, forging ahead and being brave in innovation, and constantly achieving new leaps and breakthroughs in enterprise development.